Rho-kinase inhibition reduces neointima formation after vascular injury by enhancing Bax expression and apoptosis.
D000577:Amides / Q000008:administration & dosage / Q000493:pharmacokinetics; D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology*; D020212:Carotid Artery Injuries; D002404:Catheterization / Q000009:adverse effects; D004730:Endothelium, Vascular / Q000166:cytology; D015870:Gene Expression; D020287:In Situ Nick-End Labeling; D007274:Injections, Intraperitoneal; D047908:Intracellular Signaling Peptides and Proteins; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000293:injuries* / Q000473:pathology; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology*; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis* / Q000235:genetics*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis / Q000235:genetics; D011725:Pyridines / Q000008:administration & dosage / Q000493:pharmacokinetics; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors; D017539:Tunica Intima / Q000187:drug effects* / Q000254:growth & development* / Q000648:ultrastructure; D017540:Tunica Media / Q000187:drug effects / Q000254:growth & development; D015854:Up-Regulation / Q000187:drug effects / Q000502:physiology*; D051028:bcl-2-Associated X Protein; D051020:bcl-X Protein; D054460:rho-Associated Kinases
D000577:Amides; C494828:Bax protein, rat; C494813:Bcl2l1 protein, rat; D047908:Intracellular Signaling Peptides and Proteins; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D011725:Pyridines; D051028:bcl-2-Associated X Protein; D051020:bcl-X Protein; C108830:Y 27632; D017346:Protein Serine-Threonine Kinases; D054460:rho-Associated Kinases